0001209191-24-004608.txt : 20240306 0001209191-24-004608.hdr.sgml : 20240306 20240306200102 ACCESSION NUMBER: 0001209191-24-004608 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240304 FILED AS OF DATE: 20240306 DATE AS OF CHANGE: 20240306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Struthers Richard Scott CENTRAL INDEX KEY: 0001746298 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38583 FILM NUMBER: 24727816 MAIL ADDRESS: STREET 1: C/O CRINETICS PHARMACEUTICALS, INC. STREET 2: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 263744114 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-450-6464 MAIL ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-03-04 0 0001658247 Crinetics Pharmaceuticals, Inc. CRNX 0001746298 Struthers Richard Scott C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD SAN DIEGO CA 92121 1 1 0 0 President & CEO 0 Common Stock 2024-03-04 4 A 0 65000 0.00 A 250522 D Common Stock 570805 I By Family Trust 1 Common Stock 110000 I By Family Trust 2 Common Stock 110000 I By Family Trust 3 Common Stock 110000 I By Family Trust 4 Common Stock 1000 I By Spouse Stock Option (right to buy) 43.51 2024-03-04 4 A 0 240000 0.00 A 2034-03-03 Common Stock 240000 240000 D The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2025. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 4, 2024. /s/ Marc Wilson, as attorney-in-fact 2024-03-06